chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Hospitalized 11/26/2021; COVID-19 positive 11/26/2021; fully vaccinated  BRIEF OVERVIEW: Discharge Provider: MD Primary Care Provider at Discharge: PA-C Admission Date: 11/26/2021 Discharge Date: 12/01/2021   DISCHARGE DIAGNOSES 1. COVID-19 2. Dementia 3. Diabetes   DETAILS OF HOSPITAL STAY: HOSPITAL COURSE: Patient is a 92 y.o. male who presented via EMS due to increasing weakness and being unable to get out of his chair to use the bathroom. He was COVID positive on admission. Wife was also sick with COVID. He was not hypoxic throughout his stay. He worked with PT/OT. At baseline strength upon discharge.    Upon admission, he had apparent impaired memory. Wife noted increasing memory loss over the past few years. MRI brain showed mild atrophy and white matter small vessel ischemic changes. MocA of 8/30, BCRS 24/35, MIS 0/15, Cog-Log 9/30. Patient with no legal guardian, paperwork started and wife has hearing date for guardianship. Although patient recognized that his wife and daughter would make his medical decisions if he were unable, he would not sign for that. Family and patient felt strongly that he would do best at home. Patient to receive home health services and private duty nursing at home.
This case was reported by a physician, via a GSK sales representative, that described the occurrence of arthralgia in a subject of unspecified age and gender, who was vaccinated with influenza virus vaccine (manufacturer unspecified). On an unspecified date, the subject received unspecified dose of Flu vaccine (unknown). At an unspecified time after vaccination with Flu vaccine, the subject experienced severe arthralgia. A physician reported to a sales representative that the subject experienced severe arthralgia that required treatment with Prednisone after receiving a flu vaccine. The reporting representative had limited information and was not certain that the flu vaccine received was FLUARIX. At the time of reporting, the outcome of the event was unspecified.
Mtr called 3/18/11 and reported that pt has had occasional shaking episodes since yesterday. Mtr reports he has not had any of these episodes before he took his last immunizations. Mtr reports "slight" elevated temp. Mtr denies any other symptoms. Mtr reported that the child was shaking so bad last night that he had difficulty eating. Child has not been to see MD. Mtr contributes symptoms due to extra MMR pt. received at visit. Mtr advised to take child to MD immediately.
Significant muscular pain and tightness in low back and R hip. Tx's with NASID and ice.
48 hours of fever, body aches, chills, fatigue, ("flu-like" symptoms), and 5+ days of also large swelling of lymph node in right armpit and generalized soft tissue swelling of medial aspect of right arm and upper side of torso. Swelling is slowly resolving but there is persistent mild pain in the armpit that extends on the medial side of the right arm from armpit to elbow.
Same day as second shot, Wife went out and absconded with my child, She remains delusional, I am not 100% certain this is vaccine related but if the live virus can cause psychotic or psychosis, I think our government should be aware of these possibly deadly reactions, I still do not feel normal after my vaccine was administered on the same day,
About 24 hours after the vaccine injection felt like something stuck in throat and chest hurt. Progressed in 30 minutes to pain in chest and head, swallowing painful, whole body and eyes itching and felt irritable. Symptoms continued for 24 hours.
Painful body and joint cramps aches fingers arms hands legs feet toes neck hips shoulders.   Mild headache.   Stomach nausea.    Very tired
Information has been received from a Registered nurse, who was told by a patient's husband there was an unspecified number of patients who had walked into the clinic with the same symptoms as his wife (WAES 0909USA02373) after receiving a dose of PNEUMOVAX. The wife's symptoms included: Fingers tingling, pain that went up to the elbow and nausea. The nurse had considered the symptoms to be were considered to be disabling because the patient could not move her arm. Attempts are being made to obtain additional identifying information to distinguish the individual patients mentioned in this report. Additional information will be provided if available. This is one of several reports from the same source. Additional information has been requested.
Patient received 0.2ml of undiluted Pfizer (5-11yr) Covid-19 vaccine. Spoke with patient's guardian when error was discovered. Situation explained to parent and all questions answered to their satisfaction. Dr. notified. Parents encouraged to reach out to PCP or Medical Center for further questions or concerns. Parent verbalized understanding and has no further concerns at this time.
Information was received on 09-JUL-2018 from a lawyer regarding a case in litigation. A male patient, age unspecified, was inoculated with ZOSTAVAX in 2014 by a physician as recommended for routine adult health maintenance for prevention of shingles. It did not prevent shingles as intended and subsequently the patient contracted a persistent strain of herpes zoster. In 2015 the patient was treated at a physician office for a blistering vesicular outbreak which was then diagnosed as herpes zoster, or shingles. As a direct and proximate result of ZOSTAVAX or despite receiving ZOSTAVAX for prevention of shingles, the patient suffered painful injuries and damages and required extensive medical care and treatment. As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses, pain, suffering and other damages. Additional information has been requested.
fever 99.8 within 3 hours, chills, nausea, fatigue lasting about 30 hrs
Initial and follow-up information has been received from a registered nurse and a physician concerning a 73 year old female patient who on 05-SEP-2008 was vaccinated with a dose of VARIVAX (Oka/Merck) in the left deltoid (lot number reported as 662970/1207X, which is a validated lot number for ZOSTAVAX (Oka/Merck) not VARIVAX (Oka/Merck) (injection route not reported). On 07-Oct-2008 the patient was inadvertently vaccinated with a second dose of VARIVAX (Oka/Merck) (lot number also reported as 662970/1270X) (injection site and route not reported). It was reported that the patient was supposed to receive ZOSTAVAX (Oka/Merck) (MSD). The patient had not experienced any known symptoms. Additional information is not expected.
Systemic: Dizziness / Lightheadness-Medium, Systemic: Fainting / Unresponsive-Severe, Systemic: Flushed / Sweating-Medium, Additional Details: 4 minutes after administration, he got lightheaded, fainted, fell out of his chair, and hit the ground hard. he sat up and we called EMTs and kept him talking, they said he had low blood pressure and took him to the hospital.
Systemic: Allergic: Anaphylaxis-Medium, Systemic: Allergic: Difficulty Breathing-Medium, Systemic: Allergic: Difficulty Swallowing, Throat Tightness-Medium, Systemic: pt had difficulty with previous vaccines, however risk verses benefit of not receiving vaccine could be life threatening for patient if to obtain covid-Medium, Additional Details: pt had a previous anaphylactic reaction to 1st dose of covid, informed me that she wanted to continue with vaccine. we prepped emergency products. pt's throat started to swell, gave 1st dose of epipen. waiting 5 mins, gave 2nd dose so patient swelling  went completely down. pt immediately felt better. she was monitored for 30 minutes, offered benadryl (pt couldn't take benadryl), gave zyrtec and water until better. pt was extremely satisfied with care.
Rapid heart rate approximately 1 hr after administration of vaccine.; This is a spontaneous report from a non-contactable other HCP (patient). This 36-year-old female other HCP reported for herself that she received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via intramuscular at right arm on 29Dec2020 at single dose for COVID-19 immunization. Facility type of vaccine was hospital. Medical history included known allergies to shrimp. Concomitant medication included lamotrigine. No other vaccine in four weeks. No covid prior vaccination. No covid tested post vaccination. Patient experienced rapid heart rate approximately 1 hr after administration of vaccine on 29Dec2020. No treatment was received. It was reported as non-serious. Outcome of event was recovered in Dec2020.   No follow-up attempts are possible.; information about lot/batch number cannot be obtained.
Generalized redness in the upper arm; Generalized itchiness in the upper arm; injected upper arm was warm to touch; injected arm very itchy; injected upper arm was red; injected upper arm was painful; This spontaneous case was reported by a consumer and describes the occurrence of ERYTHEMA (Generalized redness in the upper arm), PRURITUS (Generalized itchiness in the upper arm), INJECTION SITE WARMTH (injected upper arm was warm to touch), INJECTION SITE PRURITUS (injected arm very itchy) and INJECTION SITE ERYTHEMA (injected upper arm was red) in a 75-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. unknown) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included No adverse event (No medical history provided.). Concomitant products included WARFARIN, SIMVASTATIN, LOSARTAN, LEVOTHYROXINE and METOPROLOL SUCCINATE (TOPROL XL).   On 11-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) at an unspecified dose. On 20-Feb-2021, the patient experienced ERYTHEMA (Generalized redness in the upper arm), PRURITUS (Generalized itchiness in the upper arm), INJECTION SITE WARMTH (injected upper arm was warm to touch), INJECTION SITE PRURITUS (injected arm very itchy), INJECTION SITE ERYTHEMA (injected upper arm was red) and INJECTION SITE PAIN (injected upper arm was painful). On 27-Feb-2021, ERYTHEMA (Generalized redness in the upper arm), PRURITUS (Generalized itchiness in the upper arm), INJECTION SITE WARMTH (injected upper arm was warm to touch), INJECTION SITE PRURITUS (injected arm very itchy), INJECTION SITE ERYTHEMA (injected upper arm was red) and INJECTION SITE PAIN (injected upper arm was painful) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) and mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) was unknown.       Treatment includes Gold bond anti-itch lotion.   Most recent FOLLOW-UP information incorporated above includes: On 01-Mar-2021: NNI
Vaccine that was given after the expiration date.; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Vaccine that was given after the expiration date.) in a 70-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 091D21A) for COVID-19 vaccination.     No Medical History information was reported.    In October 2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In October 2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Vaccine that was given after the expiration date.). In October 2021, EXPIRED PRODUCT ADMINISTERED (Vaccine that was given after the expiration date.) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant product information was not provided. Treatment information was not reported.
moderna COVID-19 vaccine   EUA  mental fogginess.  no physical symptoms.  not tired.    for example,  I usually update my financial records to the nearest dollar.   I left  the information several dollars out of balance.   I lost interest in  personal phone calls after 10  minutes.
exceed dosing interval; rapid heart beat; This spontaneous case was reported by a consumer and describes the occurrence of HEART RATE INCREASED (rapid heart beat) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (exceed dosing interval) in a 67-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031M20A) for COVID-19 vaccination.     No Medical History information was reported.    On 10-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 10-Feb-2021, the patient experienced HEART RATE INCREASED (rapid heart beat). On 17-Mar-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (exceed dosing interval). At the time of the report, HEART RATE INCREASED (rapid heart beat) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (exceed dosing interval) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications was mentioned.  No treatment information was provided.
Patient reported today that she developed a large area of bruising the day after injection, I asked her if she has pain in the area and she needs to contact her physician to follow up.
Develop Bells Paralisis.  5 days after second dose. Was taken to Er, and hospitalized 1 day.
Swelling and redness at the site noticed 6 days post vaccination.  Warm to the touch.  Redness was traveling down the arm.  Arm still red and swollen 8 days post vaccination.
pain in the back of his lower right leg.; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team.  A 6 year-old male patient received bnt162b2 (BNT162B2), administration date 07Jan2022 (Lot number: FK5127) at the age of 6 years as dose 2, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (Dose: 1st , Lot Number / Expiry Date: FK5127/unknown, Route, Anatomical Location: unknown), administration date: 18Dec2021, when the patient was 6 years old, for COVID-19 immunization. The following information was reported: PAIN IN EXTREMITY (non-serious) with onset 08Jan2022, outcome "not recovered", described as "pain in the back of his lower right leg.".  Additional information: Caller calling on behalf of his friend's son. He reports his friend's 7 y/o son received their first Pfizer pediatric Covid vaccine dose on 07Jan2022 at 3 or 4 pm. The following day, 08Jan2022 he developed pain in the back of his lower right leg. He wants to know if this could be because of the vaccine.  Follow-up attempts are completed. No further information is expected.
reoccurring muscle tightening in shoulders, back and midrift areas affects movement balance Started day after injection-end Jan 07-Still occurring 5/27/07
Joint pain, swelling, stiffness in the am, part all days. 2 weeks after shot.
After a few minutes, my vision started to blur in focus.  The regular left leg burning became more intense. I became more off-balance in gait. Within a day or two, I started to experience sharp quick pains in my left arm.  The pains in both my left arms and hands grew excruciating over the next 2 two weeks.
Three weeks after the second Moderna shot experienced Epileptic Seizures occurred while sleeping. 911 was called.  visit to the ER.  First occurrences within three weeks of second vaccination.  Two other seizures three months later.  one other seizure six month later.  no history of seizures in the past nor family history of seizures.
Extreme Vertigo, nausea started three weeks after booster  Taking antivert as needed.
Patient was supposed to receive the pediatric dose of Pfizer (1st booster, 3rd dose) but accidentally received the adult Pfizer 3rd Booster dose.
occipital neuralgia; body heat; Aches in my legs; Spinal pain; Fatigue; This is a spontaneous report from a contactable consumer, the patient. A 75-year-old non-pregnant female patient received her first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: unknown), in left arm on 11Mar2021 at 05:15 (at the age of 75-year-old), as single dose for COVID-19 immunisation. Medical history of the patient included lyme disease, trigeminal neuralgia and meningioma. The patient was allergic to some unspecified antibiotics. The concomitant medications were not reported. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination the patient was not diagnosed with COVID-19. Since vaccination, the patient was not tested for COVID-19. On an unspecified date in Mar2021, the patient experienced occipital neuralgia, body heat, aches in legs, spinal pain and fatigue. No treatment was received for the reported events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events occipital neuralgia, body heat, aches in legs, spinal pain and fatigue was not recovered at the time of this report.  Information about lot/batch number cannot be obtained. No further information is expected.
Redness, swelling and soreness increasing in size for three days.  Round and about 4 inches around. Pain at injection site.  Flu like symptoms. Redness and swelling and pain still present on day 4
p/about 36hr acute pain in wrist, arms, legs & feet from muscle spasms;this lasted for approx 5 days;2 trips to ER, pain controlled by APAP 3;
Headache at 2:30 PM on 10/13.  Headache lasted until the evening. At 9:00 pm, neck numbness with numbness moving up face, entire face numb by noon on 10/14.  Improvement noted, but residual numbness remains lower face (chin/neck).
The 2nd dose was originally scheduled on 17May2021. I would like to know when I can get the second dose of the vaccine.; I tested positive; I tested positive; This is a spontaneous report from a contactable other hcp (patient). A patient of unspecified age and gender received first dose of bnt162b2 (PFIZER- BIONTECH COVID- 19 VACCINE, Solution for injection, Batch/Lot number was not reported), dose 1 via an unspecified route of administration on 26Apr2021 as 1st dose, single dose for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. On 13May2021, the patient was tested positive for covid-19. The patient received the 1st dose of the vaccine on 26Apr2021, and on 13May2021, patient was tested positive. The results came back negative on 28May2021. The 2nd dose was originally scheduled on 17May2021. The patient underwent lab tests and procedures which included sars-cov-2 test: positive on 13May2021, sars-cov-2 test: negative on 28May2021. Patient would like to know when can get the second dose of the vaccine. The outcome of the event tested positive was recovered on 28May2021 and unknown for other events.  Information on the lot/batch number has been requested.; Sender's Comments: The efficacy of a drug varies from patient to patient and can be affected by different factors; however, a contributory role of the suspect product BNT162B2 or comirnaty to the reported event drug ineffective and covid-19 cannot be ruled out.
Reporter confirmed that patients had been administered doses while the temperature excursion assessment was ongoing.; patient was administered Moderna vaccine while temperature excursion assessment was ongoing; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (Reporter confirmed that patients had been administered doses while the temperature excursion assessment was ongoing.) and POOR QUALITY PRODUCT ADMINISTERED (patient was administered Moderna vaccine while temperature excursion assessment was ongoing) in a 57-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Reporter confirmed that patients had been administered doses while the temperature excursion assessment was ongoing.) and POOR QUALITY PRODUCT ADMINISTERED (patient was administered Moderna vaccine while temperature excursion assessment was ongoing). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (Reporter confirmed that patients had been administered doses while the temperature excursion assessment was ongoing.) and POOR QUALITY PRODUCT ADMINISTERED (patient was administered Moderna vaccine while temperature excursion assessment was ongoing) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported. No treatment medications were reported.  The reporter stated that their facility had not been able to download the digital data logger, they had been put on hold by at the moment. There had been no power outages that would have impacted the Moderna vaccine.  It was reported that, the facility was unable to download the digital data logger, they would need to treat this issue as a temperature excursion. The data logger was unable to download for the months of Dec-2021, Jan-2022, and Feb-2022. The reporter did not have any questions and wanted to report this to Moderna.  The reporter stated that no adverse reactions were reported by any patients.
PEA Cardiac Arrest due to bilateral pulmonary emboli with cor pulmonale complicated by obstructive shock causing acute hypoxic encephalopathy, acute renal failure, acute respiratory failure and acute liver failure. Remains on ventilator and requiring multiple vasopressors. Family is planning to withdraw care.
Approximately 21 hours after receiving the vaccine, my lips started to swell . I also experienced fever, chills, muscle aches, which I know is normal. I contacted my primary care physician due to the lip swelling and they prescribed me Benadryl and prednisone. I did nothing out of the ordinary, nor did I eat any new foods or take any different medication. I did get lip injections done in January 2020.
Patient received Moderna COVID-19 vaccine #1 on 4/1/2021 at  Park. Vaccine given 1140. Patient developed throat tightness. She was seen by Dr.  and  RN. She was given Benadryl 50 mg po (25 mg dose x2) and Pepcid 20 mg (10 mg dose x2). EMS was called and patient was taken to ED.
upper right arm developed red mark and became hard; upper right arm developed red mark and became hard; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE INDURATION (upper right arm developed red mark and became hard) and VACCINATION SITE ERYTHEMA (upper right arm developed red mark and became hard) in a 67-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 04-Feb-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 05-Feb-2021, the patient experienced VACCINATION SITE INDURATION (upper right arm developed red mark and became hard) and VACCINATION SITE ERYTHEMA (upper right arm developed red mark and became hard). The patient was treated with IBUPROFEN ongoing from February 2021 for Adverse event, at an unspecified dose and frequency. At the time of the report, VACCINATION SITE INDURATION (upper right arm developed red mark and became hard) and VACCINATION SITE ERYTHEMA (upper right arm developed red mark and became hard) was resolving.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medication was not reported.
Pt w/ Hx Sulfa and Shellfish allergies.  Pt c/o itchy throat.  BP 139/79, HR 82, RR 16 -- > 127/65, 79, 16.  Pt indicated that the itchiness was decreasing and pt was not in distress.  Pt stable and released from the vaccination site.